This study investigated antiviral resistance by sequencing UL97 and UL54 in cytomegalovirus (CMV) strains from haematology and hematopoietic stem cell transplant (HSCT) patients. Fifty-one samples from 48 patients (21 paediatric and 27 adult) with CMV DNA ≥1000 IU/mL and persistent viremia despite therapy were analysed. Resistance-associated mutations were identified in 6/48 patients (12.5%), all HSCT recipients - three paediatric and three adults. Detected mutations included UL97 (A591V, E596G and C603W), combined UL97 (M460I and C592G) and UL54 (F412L) mutations, and a UL54 (L957F) mutation. Additionally, 28 patients harboured 11 previously reported variants not associated with resistance. Novel UL97 (n = 18) and UL54 (n = 20) variants were also identified. In conclusion, prevalence of CMV antiviral resistance was 14.2% in CMV-infected HSCT recipients, slightly higher in paediatric patients. Detection of known and novel UL97/UL54 mutations highlights the importance of monitoring and the need for studies to assess the clinical impact of novel variants.
Çevik et al. (Sun,) studied this question.